- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.10. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 12.10. | AB&B BIO-TECH-B (02627): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) CONTINUED SUSPENSION OF TRADING | 1 | HKEx | ||
| 30.09. | AB&B BIO-TECH-B (02627): QUARTERLY UPDATE ON RESUMPTION PROGRESS AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 23.09. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 23.09. | AB&B BIO-TECH-B (02627): (I) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER (II) NOMINATION OF EXECUTIVE DIRECTORS (III) APPOINTMENT OF ... | 1 | HKEx | ||
| 31.08. | AB&B BIO-TECH-B (02627): INSIDE INFORMATION: (1) FURTHER DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND ... | 1 | HKEx | ||
| 30.06. | AB&B BIO-TECH-B (02627): QUARTERLY UPDATE ON RESUMPTION PROGRESS; POSTPONEMENT OF THE 2025 ANNUAL GENERAL MEETING; AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 23.06. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| 05.06. | AB&B BIO-TECH-B (02627): APPOINTMENT OF INDEPENDENT INVESTIGATOR AND INDEPENDENT INTERNAL CONTROL CONSULTANT | 1 | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 (2) ABOLITION OF THE SUPERVISORY COMMITTEE, AMENDMENTS TO ... | - | HKEx | ||
| 13.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT) | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF | 2 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): (1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE ... | 1 | HKEx | ||
| 07.05. | AB&B BIO-TECH-B (02627): NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 | - | HKEx |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | 0,00 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,510 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ABSCI | 12,100 | 0,00 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus |
Das Unternehmen AB&B BIO-TECH CO LTD JS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.